Proprietary AI analyst is now available
- Public Comps
- Carl Zeiss Meditec
Carl Zeiss Meditec Valuation Multiples
Discover Carl Zeiss Meditec's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Ambu, TransMedics, Double Medical Technology, Autobio Diagnostics and more.
Carl Zeiss Meditec Overview
About Carl Zeiss Meditec
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
Founded
1977
HQ

Employees
4.8K
Website
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialCarl Zeiss Meditec Financials
Carl Zeiss Meditec reported last 12-month revenue of $3B and EBITDA of $373M.
In the same LTM period, Carl Zeiss Meditec generated $1B in gross profit, $373M in EBITDA, and $131M in net income.
Revenue (LTM)
Carl Zeiss Meditec P&L
In the most recent fiscal year, Carl Zeiss Meditec reported revenue of $3B and EBITDA of $424M.
Carl Zeiss Meditec is profitable as of last fiscal year, with gross margin of 52%, EBITDA margin of 16%, and net margin of 6%.
Financial data powered by Morningstar, Inc.
Carl Zeiss Meditec Stock Performance
Carl Zeiss Meditec has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Carl Zeiss Meditec's stock price is $30.25.
Carl Zeiss Meditec share price increased by 0.2% in the last 30 days, and decreased by 54.0% in the last year.
Carl Zeiss Meditec has an EPS (earnings per share) of $1.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.8% | 0.2% | 5.9% | -54.0% | $1.90 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCarl Zeiss Meditec Valuation Multiples
Carl Zeiss Meditec trades at 1.1x EV/Revenue multiple, and 7.4x EV/EBITDA.
EV / Revenue (LTM)
Carl Zeiss Meditec Financial Valuation Multiples
As of June 10, 2026, Carl Zeiss Meditec has market cap of $3B and EV of $3B.
Carl Zeiss Meditec has a P/E ratio of 20.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Carl Zeiss Meditec Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Carl Zeiss Meditec Margins & Growth Rates
Carl Zeiss Meditec decreased revenue by 4% and EBITDA by 17% in the last fiscal year.
In the most recent fiscal year, Carl Zeiss Meditec reported gross margin of 52%, EBITDA margin of 16%, and net margin of 6%.
Carl Zeiss Meditec Margins
Carl Zeiss Meditec Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Carl Zeiss Meditec Operational KPIs
Carl Zeiss Meditec's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Carl Zeiss Meditec's Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Carl Zeiss Meditec's Rule of X is 14% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Carl Zeiss Meditec Competitors
Carl Zeiss Meditec competitors include Ambu, TransMedics, Double Medical Technology, Autobio Diagnostics, Sinbon Electronics, Tecan Group, MGI Tech, Establishment Labs, Insight Lifetech and Axogen.
Most Carl Zeiss Meditec public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.7x | 14.7x | 14.7x | |||
| 4.9x | 4.5x | 18.3x | 18.8x | |||
| 6.0x | 5.6x | 16.6x | 14.0x | |||
| 3.8x | 3.7x | 9.4x | 9.6x | |||
| 2.5x | 2.3x | 16.8x | 18.4x | |||
| 2.1x | 2.1x | 13.5x | 13.5x | |||
| 6.2x | 5.9x | 107.2x | 74.3x | |||
| 12.1x | 10.8x | (179.3x) | (9436.9x) | |||
This data is available for Pro users. Sign up to see all Carl Zeiss Meditec competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Carl Zeiss Meditec
Carl Zeiss Meditec has acquired 11 companies to date.
Last acquisition by Carl Zeiss Meditec was on December 15th 2023. Carl Zeiss Meditec acquired Dutch Ophthalmic Research Center for $1B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Carl Zeiss Meditec
| Description | Dutch Ophthalmic Research Center is a Netherlands-based manufacturer of precision instruments for vitreoretinal, cataract, and glaucoma surgeries. Headquartered in Zuidland, it exports micro-manipulators, vitrectomy probes, and infusion systems to over 100 countries. | Ncam is a London-based developer of camera tracking systems for virtual production in film, television, and live events. Its technology integrates lightweight sensor bars with cameras to deliver sub-millimeter accurate 6DoF tracking using natural visual features. Compatible with Unreal Engine, Notch, and Disguise, Ncam enables real-time AR overlays and LED volume workflows. Deployed on productions like The Mandalorian and Westworld, it supports unrestricted camera movement indoors and outdoors. | Lenso is a Warsaw-based distributor of GOM optical measuring systems for industrial quality control, product development, and production. The company supplies 3D scanning and inspection technologies from the German brand GOM to clients worldwide in automotive, aerospace, and manufacturing sectors. Services include system integration, training, and support for applications like deformation analysis and reverse engineering. | Katalyst Surgical is a Chesterfield, Missouri-based manufacturer of titanium ophthalmic instruments founded in 2010. The company supplies cannulas, forceps, hooks, LASIK tools, needle holders, phaco choppers, scissors, and speculums to surgeons worldwide through its online catalog. Its precision-engineered products cater to cataract, vitreoretinal, and refractive procedures. | |
| HQ Country | |||||
| HQ City | Rotterdam | London | Poznan | Saint Louis, MO | |
| Deal Date | 15 Dec 2023 | 18 Jul 2023 | 1 Jan 2023 | 19 Apr 2022 | |
| Valuation | $1B | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Carl Zeiss Meditec acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Carl Zeiss Meditec
Carl Zeiss Meditec has invested in 7 companies to date.
Latest investment by Carl Zeiss Meditec was on July 10th 2025. Carl Zeiss Meditec invested in CREAL in their $9M Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by Carl Zeiss Meditec
| Description | CREAL is a Delft-based developer of near-eye light-field displays for virtual and mixed reality headsets. The company's optics technology delivers true optical depth to reduce eye strain, nausea, and vergence-accommodation conflict. Its compact modules integrate into devices from partners like Varjo, enabling natural focus cues with low manufacturing complexity. | MakerVerse is a San Francisco-based platform for on-demand sourcing of CNC-machined, 3D-printed, and injection-molded parts from vetted global manufacturers. Launched in 2023, it provides instant quotes, DFM analysis, and delivery tracking for engineers at startups and enterprises across the United States. | Scantinel Photonics is a Dresden-headquartered developer of coherent FMCW LiDAR sensors for autonomous vehicles and robotics. The company's solid-state technology combines frequency-modulated continuous wave ranging with spectral beam steering to produce high-resolution 3D environmental maps at ranges up to 200 meters. Scantinel partners with automotive OEMs for ADAS integration, emphasizing automotive-grade reliability and cost efficiency. | Precise Bio is a regenerative medicine firm that engineers 4D bio-fabricated tissues and organs using precision extrusion printing technology. Winston-Salem-headquartered, the company commercializes products like PreciVasc for vascular grafts and cardiac patches for heart repair. Precise Bio raised $12 million in Series A funding in 2022 to expand its pipeline toward full organ constructs. Its platform integrates living cells with dynamic biomaterials responsive to physiological conditions. | |
| HQ Country | |||||
| HQ City | Lausanne | Berlin | Ulm | Winston Salem, NC | |
| Deal Date | 10 Jul 2025 | 4 Apr 2023 | 24 Nov 2022 | 18 Jul 2022 | |
| Round | Strategic investment | Series A | Series A | Series A | |
| Raised | $9M | $10M | $10M | $12M | |
| Investors | Carl Zeiss Meditec | Ninepointfive; Siemens Energy; Carl Zeiss Meditec | PhotonDelta; Scania Growth Capital; Carl Zeiss Meditec | Carl Zeiss Meditec; K20 Fund | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Carl Zeiss Meditec investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Carl Zeiss Meditec
| When was Carl Zeiss Meditec founded? | Carl Zeiss Meditec was founded in 1977. |
| Where is Carl Zeiss Meditec headquartered? | Carl Zeiss Meditec is headquartered in Germany. |
| How many employees does Carl Zeiss Meditec have? | As of today, Carl Zeiss Meditec has over 4K employees. |
| Is Carl Zeiss Meditec publicly listed? | Yes, Carl Zeiss Meditec is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Carl Zeiss Meditec? | Carl Zeiss Meditec trades under AFX ticker. |
| When did Carl Zeiss Meditec go public? | Carl Zeiss Meditec went public in 2000. |
| Who are competitors of Carl Zeiss Meditec? | Carl Zeiss Meditec main competitors include Ambu, TransMedics, Double Medical Technology, Autobio Diagnostics, Sinbon Electronics, Tecan Group, MGI Tech, Establishment Labs, Insight Lifetech, Axogen. |
| What is the current market cap of Carl Zeiss Meditec? | Carl Zeiss Meditec's current market cap is $3B. |
| What is the current revenue of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months revenue is $3B. |
| What is the current revenue growth of Carl Zeiss Meditec? | Carl Zeiss Meditec revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Carl Zeiss Meditec? | Current revenue multiple of Carl Zeiss Meditec is 1.1x. |
| What is the current EBITDA of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months EBITDA is $373M. |
| What is Carl Zeiss Meditec's EBITDA margin? | Carl Zeiss Meditec's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Carl Zeiss Meditec? | Current EBITDA multiple of Carl Zeiss Meditec is 7.4x. |
| What is the current FCF of Carl Zeiss Meditec? | Carl Zeiss Meditec's last 12 months FCF is $127M. |
| What is Carl Zeiss Meditec's FCF margin? | Carl Zeiss Meditec's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Carl Zeiss Meditec? | Current FCF multiple of Carl Zeiss Meditec is 21.8x. |
| How many companies Carl Zeiss Meditec has acquired to date? | As of June 2026, Carl Zeiss Meditec has acquired 11 companies. |
| What was the largest acquisition by Carl Zeiss Meditec? | $1B acquisition of Dutch Ophthalmic Research Center on 15th December 2023 was the largest M&A Carl Zeiss Meditec has done to date. |
| What companies Carl Zeiss Meditec acquired? | Carl Zeiss Meditec acquired Dutch Ophthalmic Research Center, Aaren Scientific, Veracity Innovations, CAPTURE 3D, Lenso, GUARDUS, GOM Metrology, NCam, Katalyst Surgical, Kogent Surgical, and 1 other company. |
| In how many companies Carl Zeiss Meditec has invested to date? | As of June 2026, Carl Zeiss Meditec has invested in 7 companies. |
| What was the last Carl Zeiss Meditec investment? | On 10th July 2025 Carl Zeiss Meditec invested in CREAL, participating in a $9M Strategic investment round. |
| In what companies Carl Zeiss Meditec invested in? | Carl Zeiss Meditec invested in Precise Bio, MakerVerse, Scantinel Photonics, Senorics, CREAL, Audioptics Medical, and predict.io. |
See public comps similar to Carl Zeiss Meditec
Lists including Carl Zeiss Meditec
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





